Selected Grants
BIO89-100-132 The ENLIGHTEN-Cirrhosis Pro00116849
Clinical TrialPrincipal Investigator · Awarded by 89bio, Inc · 2024 - 20311404-0044, A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants NASH/MASH and (F2) -(F3) stage of liver fibrosis
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2026 - 2031ZENITH-1 Protocol number: 301160 Protocol tile: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunct
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline LLC · 2026 - 2030ZENITH-2 Protocol number: 306246 Protocol title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic D
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline LLC · 2026 - 2030BIO89-100-131 The ENLIGHTEN-Fibrosis Study Pro00115755. A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis.
Clinical TrialPrincipal Investigator · Awarded by 89bio, Inc · 2024 - 2029Nonalcoholic Fatty Liver Disease (NAFLD) in Polycystic Ovary Syndrome: The Role of Androgens on Visceral Fat, Lipid Metabolites, and Liver Injury in Young Women
ResearchPrincipal Investigator · Awarded by University of California - San Francisco · 2023 - 2028Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis
Clinical TrialCollaborator · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2021 - 2027Generating Evidence to Assess the Optimal Application of NIS2+TM within Real-World Workflows Pro00112444
Clinical TrialPrincipal Investigator · Awarded by The Kinetix Group (TKG) · 2024 - 2027ELF Study Pro00115897. Implementation of ELF in Type 2 Diabetes Clinics to Identify Patients with Liver Fibrosis Secondary to Metabolic Dysfunction Associated Steatotic Liver Disease.
ResearchPrincipal Investigator · Awarded by Clinetic, Inc · 2025 - 2026External Relationships
- Boehringer Ingleheim
- Madrigal-19
- NovoNordisk
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.